Idenix Pharmaceuticals, Inc.
_________________________________________________________________________________
Idenix Pharmaceuticals, Inc. Financial Snapshot
Operating Performance
Fast Facts
60 Hampshire Street, Cambridge, The company reported revenue of US$7 million
Headquarters Address
02139,United States of America during the fiscal year 2011 (2011). The company's
revenue declined at a compounded rate of 43.46%
Telephone + 1 617 9959800
during 2007–2011, with an annual decline of 32.00%
over 2010. In 2011, the company recorded an
Fax + 1 617 9959801 operating margin of -768.35%, as against -613.64% in
2010.
Website www.idenix.com
Ticker Symbol, Stock Exchange IDIX, NASDAQ Revenue and Margins
Number of Employees 105
Fiscal Year End December
Revenue (in US$ million) 7
SWOT Analysis
Strengths Weaknesses
In-house manufacturing capabilities Limited operations
Patent portfolio Overdependence on Novartis
Strong focus on research and
Poor financial performance
development
Opportunities Threats
Increasing healthcare expenditure Tightening regulations
Increasing hepatitis C market Uncertain R&D outcomes
Product development pipeline
___________________________________________________________________________________________
Idenix Pharmaceuticals, Inc. - SWOT Profile Page 1
Idenix Pharmaceuticals, Inc.
_________________________________________________________________________________
TABLE OF CONTENTS
1 Business Analysis ................................................................................................................................... 5
1.1 Company Overview ......................................................................................................................................... 5
1.2 Business Description ....................................................................................................................................... 5
1.3 Major Products and Services ........................................................................................................................... 6
2 Analysis of Key Performance Indicators ............................................................................................... 7
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators ....................................... 7
2.2 Key Financial Performance Indicators ............................................................................................................ 10
2.2.1 Revenue and Operating Profit.................................................................................................................... 10
2.2.2 Asset and Liabilities ................................................................................................................................... 11
2.2.3 Solvency ................................................................................................................................................... 12
2.3 Competitive Benchmarking ............................................................................................................................ 13
3 SWOT Analysis ...................................................................................................................................... 14
3.1 SWOT Analysis - Overview ............................................................................................................................ 14
3.2 Strengths ....................................................................................................................................................... 14
3.3 Weaknesses .................................................................................................................................................. 14
3.4 Opportunities ................................................................................................................................................. 15
3.5 Threats .......................................................................................................................................................... 15
4 History .................................................................................................................................................... 16
5 Key Employees ...................................................................................................................................... 17
6 Key Employee Biographies ................................................................................................................... 18
7 Locations and Subsidiaries .................................................................................................................. 19
7.1 Head Office ................................................................................................................................................... 19
7.2 Other Locations and Subsidiaries .................................................................................................................. 19
8 Appendix ................................................................................................................................................ 21
8.1 Methodology .................................................................................................................................................. 21
8.2 Ratio Definitions ............................................................................................................................................ 21
8.3 Disclaimer ..................................................................................................................................................... 25
___________________________________________________________________________________________
Idenix Pharmaceuticals, Inc. - SWOT Profile Page 2
Idenix Pharmaceuticals, Inc.
__________________________________________________________________________________________
List of Tables
Table 1: Major Products and Services ............................................................................................................................ 6
Table 2: Key Ratios - Annual ........................................................................................................................................... 7
Table 3: Key Ratios - Interim ........................................................................................................................................... 9
Table 4: Key Capital Market Indicators ............................................................................................................................ 9
Table 5: History ............................................................................................................................................................. 16
Table 6: Key Employees ................................................................................................................................................ 17
Table 7: Key Employee Biographies .............................................................................................................................. 18
Table 8: Subsidiaries ..................................................................................................................................................... 19
Table 9: Locations ......................................................................................................................................................... 19
___________________________________________________________________________________________
Idenix Pharmaceuticals, Inc. - SWOT Profile Page 3
Idenix Pharmaceuticals, Inc.
__________________________________________________________________________________________
List of Figures
Figure 1: Revenue and Operating Profit ......................................................................................................................... 10
Figure 2: Financial Position ........................................................................................................................................... 11
Figure 3: Solvency......................................................................................................................................................... 12
___________________________________________________________________________________________
Idenix Pharmaceuticals, Inc. - SWOT Profile Page 4
Idenix Pharmaceuticals, Inc.
__________________________________________________________________________________________
1 Business Analysis
1.1 Company Overview
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company, based in the US. The company primarily focuses
on the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix’s
primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). Its HCV discovery
program focuses on various classes of drugs including nucleoside, nucleotide polymerase inhibitors, protease inhibitors,
non-nucleoside polymerase inhibitors, and NS5A inhibitors. The company develops products and drug candidates for the
treatment of patients with hepatitis B virus (HBV), human immunodeficiency virus (HIV) type-1, and acquired immune
deficiency syndrome (AIDS). The company has a collaboration agreement with Novartis Pharma AG under which,
Novartis develops and commercializes its HBV drug telbivudine under the Tyzeka and Sebivo brands. The company
conducts its clinical development operations and drug discovery operations in Cambridge, the US and Montpellier,
France. Idenix is headquartered in Cambridge, Massachusetts, the US.
1.2 Business Description
Idenix is a specialty pharmaceutical company, primarily focused on the discovery and development of drugs for viral and
other infectious diseases.
The company develops and manufactures products in the areas of Hepatitis B, Hepatitis C, and HIV and acquired immune
deficiency syndrome (AIDS). HCV discovery program focuses on various classes of drugs including nucleoside,
nucleotide polymerase inhibitors, protease inhibitors, non-nucleoside polymerase inhibitors, and NS5A inhibitors. The
company has a collaboration agreement with Novartis Pharma AG for the development and commercialization of
telbivudine, a drug for the treatment of HBV under the Tyzeka/Sebiv